Logo image of APDN

APPLIED DNA SCIENCES INC (APDN) Stock Fundamental Analysis

NASDAQ:APDN - Nasdaq - US03815U4094 - Common Stock - Currency: USD

0.157  0 (-2.91%)

After market: 0.1594 +0 (+1.53%)

Fundamental Rating

2

Taking everything into account, APDN scores 2 out of 10 in our fundamental rating. APDN was compared to 57 industry peers in the Life Sciences Tools & Services industry. While APDN seems to be doing ok healthwise, there are quite some concerns on its profitability. APDN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

APDN had negative earnings in the past year.
In the past year APDN has reported a negative cash flow from operations.
APDN had negative earnings in each of the past 5 years.
In the past 5 years APDN always reported negative operating cash flow.
APDN Yearly Net Income VS EBIT VS OCF VS FCFAPDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

APDN has a Return On Assets of -147.70%. This is amonst the worse of the industry: APDN underperforms 94.74% of its industry peers.
The Return On Equity of APDN (-184.96%) is worse than 87.72% of its industry peers.
Industry RankSector Rank
ROA -147.7%
ROE -184.96%
ROIC N/A
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
APDN Yearly ROA, ROE, ROICAPDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 39.34%, APDN is in line with its industry, outperforming 40.35% of the companies in the same industry.
APDN's Gross Margin has declined in the last couple of years.
APDN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
APDN Yearly Profit, Operating, Gross MarginsAPDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

6

2. Health

2.1 Basic Checks

APDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APDN has more shares outstanding
APDN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for APDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
APDN Yearly Shares OutstandingAPDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
APDN Yearly Total Debt VS Total AssetsAPDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -28.89, we must say that APDN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -28.89, APDN is doing worse than 89.47% of the companies in the same industry.
APDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.89
ROIC/WACCN/A
WACC11.32%
APDN Yearly LT Debt VS Equity VS FCFAPDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

2.3 Liquidity

APDN has a Current Ratio of 4.72. This indicates that APDN is financially healthy and has no problem in meeting its short term obligations.
APDN's Current ratio of 4.72 is fine compared to the rest of the industry. APDN outperforms 70.18% of its industry peers.
A Quick Ratio of 4.53 indicates that APDN has no problem at all paying its short term obligations.
The Quick ratio of APDN (4.53) is better than 73.68% of its industry peers.
Industry RankSector Rank
Current Ratio 4.72
Quick Ratio 4.53
APDN Yearly Current Assets VS Current LiabilitesAPDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

APDN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.04%, which is quite impressive.
Looking at the last year, APDN shows a very negative growth in Revenue. The Revenue has decreased by -58.46% in the last year.
APDN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.63% yearly.
EPS 1Y (TTM)47.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.89%
Revenue 1Y (TTM)-58.46%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%34.66%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y84.69%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year48.01%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APDN Yearly Revenue VS EstimatesAPDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
APDN Yearly EPS VS EstimatesAPDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

APDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year APDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APDN Price Earnings VS Forward Price EarningsAPDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APDN Per share dataAPDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

APDN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APPLIED DNA SCIENCES INC

NASDAQ:APDN (2/21/2025, 8:01:23 PM)

After market: 0.1594 +0 (+1.53%)

0.157

0 (-2.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)05-08 2025-05-08
Inst Owners26.59%
Inst Owner Change-38.31%
Ins Owners6.97%
Ins Owner Change0%
Market Cap8.66M
Analysts43.33
Price Target1.53 (874.52%)
Short Float %13.88%
Short Ratio1.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.6%
Min EPS beat(2)-68.93%
Max EPS beat(2)7.73%
EPS beat(4)2
Avg EPS beat(4)38.69%
Min EPS beat(4)-68.93%
Max EPS beat(4)231.65%
EPS beat(8)6
Avg EPS beat(8)44.8%
EPS beat(12)9
Avg EPS beat(12)45.8%
EPS beat(16)9
Avg EPS beat(16)14.81%
Revenue beat(2)1
Avg Revenue beat(2)1.05%
Min Revenue beat(2)-11.33%
Max Revenue beat(2)13.42%
Revenue beat(4)1
Avg Revenue beat(4)-7.42%
Min Revenue beat(4)-27.61%
Max Revenue beat(4)13.42%
Revenue beat(8)4
Avg Revenue beat(8)-6.59%
Revenue beat(12)7
Avg Revenue beat(12)0.58%
Revenue beat(16)10
Avg Revenue beat(16)-0.48%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.32
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)-5.72
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0.07
BVpS0.23
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -147.7%
ROE -184.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.34%
FCFM N/A
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
F-Score4
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.72
Quick Ratio 4.53
Altman-Z -28.89
F-Score4
WACC11.32%
ROIC/WACCN/A
Cap/Depr(3y)60.08%
Cap/Depr(5y)170.88%
Cap/Sales(3y)7.71%
Cap/Sales(5y)21.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.89%
EPS Next Y84.69%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-58.46%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%34.66%
Revenue Next Year48.01%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-71.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.41%
OCF growth 3YN/A
OCF growth 5YN/A